Immunotherapy-based neoadjuvant treatment and complication rates after radical cystectomy

IF 3.7 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International Pub Date : 2025-01-23 DOI:10.1111/bju.16662

Reuben Ben-David, Francesco Pellegrino, Reza Mehrazin, Joel Thomas, Jack Geduldig, Sarah Lidagoster, Evan B. Garden, Kyrollis Attalla, Ahmed Eraky, Paolo Zaurito, Marco Moschini, Alberto Briganti, Francesco Montorsi, John P. Sfakianos, Peter Wiklund

引用次数: 0

Abstract

To assess 30- and 90-day postoperative complication rates in patients who underwent robot-assisted radical cystectomy (RARC) after receiving novel immunotherapy-based neoadjuvant treatment.

查看原文本刊更多论文

基于免疫疗法的新辅助治疗和根治性膀胱切除术后的并发症发生率

评估机器人辅助根治性膀胱切除术（RARC）患者在接受基于新型免疫疗法的新辅助治疗后30天和90天的术后并发症发生率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BJU International 医学-泌尿学与肾脏学

CiteScore

9.10

自引率

4.40%

发文量

262

审稿时长

1 months

期刊介绍： BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.